319 related articles for article (PubMed ID: 28951560)
1. Therapeutic targeting of CK2 in acute and chronic leukemias.
Buontempo F; McCubrey JA; Orsini E; Ruzzene M; Cappellini A; Lonetti A; Evangelisti C; Chiarini F; Evangelisti C; Barata JT; Martelli AM
Leukemia; 2018 Jan; 32(1):1-10. PubMed ID: 28951560
[TBL] [Abstract][Full Text] [Related]
2. Casein Kinase II (CK2) as a Therapeutic Target for Hematological Malignancies.
Gowda C; Sachdev M; Muthusami S; Kapadia M; Petrovic-Dovat L; Hartman M; Ding Y; Song C; Payne JL; Tan BH; Dovat S
Curr Pharm Des; 2017; 23(1):95-107. PubMed ID: 27719640
[TBL] [Abstract][Full Text] [Related]
3. Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2.
Duncan JS; Litchfield DW
Biochim Biophys Acta; 2008 Jan; 1784(1):33-47. PubMed ID: 17931986
[TBL] [Abstract][Full Text] [Related]
4. Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways.
Piazza F; Manni S; Ruzzene M; Pinna LA; Gurrieri C; Semenzato G
Leukemia; 2012 Jun; 26(6):1174-9. PubMed ID: 22289987
[TBL] [Abstract][Full Text] [Related]
5. Protein kinase CK2 inhibition as a pharmacological strategy.
Borgo C; Ruzzene M
Adv Protein Chem Struct Biol; 2021; 124():23-46. PubMed ID: 33632467
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of protein kinase CK2 with the clinical-grade small ATP-competitive compound CX-4945 or by RNA interference unveils its role in acute myeloid leukemia cell survival, p53-dependent apoptosis and daunorubicin-induced cytotoxicity.
Quotti Tubi L; Gurrieri C; Brancalion A; Bonaldi L; Bertorelle R; Manni S; Pavan L; Lessi F; Zambello R; Trentin L; Adami F; Ruzzene M; Pinna LA; Semenzato G; Piazza F
J Hematol Oncol; 2013 Oct; 6():78. PubMed ID: 24283803
[TBL] [Abstract][Full Text] [Related]
7. Targeting CK2 overexpression and hyperactivation as a novel therapeutic tool in chronic lymphocytic leukemia.
Martins LR; Lúcio P; Silva MC; Anderes KL; Gameiro P; Silva MG; Barata JT
Blood; 2010 Oct; 116(15):2724-31. PubMed ID: 20660292
[TBL] [Abstract][Full Text] [Related]
8. Targeting CK2-driven non-oncogene addiction in B-cell tumors.
Mandato E; Manni S; Zaffino F; Semenzato G; Piazza F
Oncogene; 2016 Nov; 35(47):6045-6052. PubMed ID: 27041560
[TBL] [Abstract][Full Text] [Related]
9. [Casein kinase 2, the versatile regulator of cell survival].
Volodina IuL; Shtil' AA
Mol Biol (Mosk); 2012; 46(3):423-33. PubMed ID: 22888632
[TBL] [Abstract][Full Text] [Related]
10. Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia.
Song C; Gowda C; Pan X; Ding Y; Tong Y; Tan BH; Wang H; Muthusami S; Ge Z; Sachdev M; Amin SG; Desai D; Gowda K; Gowda R; Robertson GP; Schjerven H; Muschen M; Payne KJ; Dovat S
Blood; 2015 Oct; 126(15):1813-22. PubMed ID: 26219304
[TBL] [Abstract][Full Text] [Related]
11. Protein kinase CK2 regulates AKT, NF-κB and STAT3 activation, stem cell viability and proliferation in acute myeloid leukemia.
Quotti Tubi L; Canovas Nunes S; Brancalion A; Doriguzzi Breatta E; Manni S; Mandato E; Zaffino F; Macaccaro P; Carrino M; Gianesin K; Trentin L; Binotto G; Zambello R; Semenzato G; Gurrieri C; Piazza F
Leukemia; 2017 Feb; 31(2):292-300. PubMed ID: 27479180
[TBL] [Abstract][Full Text] [Related]
12. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
Izeradjene K; Douglas L; Delaney A; Houghton JA
Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and proapoptotic properties of new casein kinase II inhibitors.
Koronkiewicz M; Zukowska M; Chilmonczyk Z; Orzeszko A; Kazimierczuk Z
Acta Pol Pharm; 2010; 67(6):635-41. PubMed ID: 21229880
[TBL] [Abstract][Full Text] [Related]
14. Casein Kinase II (CK2), Glycogen Synthase Kinase-3 (GSK-3) and Ikaros mediated regulation of leukemia.
Gowda C; Soliman M; Kapadia M; Ding Y; Payne K; Dovat S
Adv Biol Regul; 2017 Aug; 65():16-25. PubMed ID: 28623166
[TBL] [Abstract][Full Text] [Related]
15. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies.
Chon HJ; Bae KJ; Lee Y; Kim J
Front Pharmacol; 2015; 6():70. PubMed ID: 25873900
[TBL] [Abstract][Full Text] [Related]
16. Protein kinase CK2 interacts with adiponectin receptor 1 and participates in adiponectin signaling.
Heiker JT; Wottawah CM; Juhl C; Kosel D; Mörl K; Beck-Sickinger AG
Cell Signal; 2009 Jun; 21(6):936-42. PubMed ID: 19233263
[TBL] [Abstract][Full Text] [Related]
17. Chemically induced degradation of CK2 by proteolysis targeting chimeras based on a ubiquitin-proteasome pathway.
Chen H; Chen F; Liu N; Wang X; Gou S
Bioorg Chem; 2018 Dec; 81():536-544. PubMed ID: 30245235
[TBL] [Abstract][Full Text] [Related]
18. Protein kinase CK2 inhibitors: a patent review.
Cozza G; Pinna LA; Moro S
Expert Opin Ther Pat; 2012 Sep; 22(9):1081-97. PubMed ID: 22908959
[TBL] [Abstract][Full Text] [Related]
19. Protein kinase CK2 in health and disease: CK2: a key player in cancer biology.
Trembley JH; Wang G; Unger G; Slaton J; Ahmed K
Cell Mol Life Sci; 2009 Jun; 66(11-12):1858-67. PubMed ID: 19387548
[TBL] [Abstract][Full Text] [Related]
20. Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specific cell-permeable peptide inhibitor.
Martins LR; Perera Y; Lúcio P; Silva MG; Perea SE; Barata JT
Oncotarget; 2014 Jan; 5(1):258-63. PubMed ID: 24473900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
